Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study
Among RA patients with DM, SGLT2i use may inherently increase the risk of UTI compared with other antidiabetics. However, the ITT analysis findings support the safety of SGLT2i selection in routine clinical practice, including in patients receiving glucocorticoids.
Authors
- Naofumi Dobashi (ORCID: https://orcid.org/0009-0004-6064-5289)
- Masataka Kudo (ORCID: https://orcid.org/0000-0002-9698-8791)
- Ken‐ei Sada (ORCID: https://orcid.org/0000-0003-1020-0818)
- Narufumi Suganuma (ORCID: https://orcid.org/0000-0003-1610-6216)
- Shigemi Morishita (ORCID: https://orcid.org/0000-0002-5887-4080)
- Sho Sasaki
Institutions
- Fukushima Medical University (JP)
- University of Kochi (JP)
- Kyoto University (JP)
- Makino Botanical Garden (JP)
- Kochi Medical School Hospital (JP)
- Misasa Onsen Hospital (JP)
- Oida Hospital (JP)
- Aso Iizuka Hospital (JP)
- Children's Specialized Hospital (US)
- Kōchi University (JP)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1093/rheumatology/keaf580
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88